Recall database
Wizcure Pharmaa PVT. LTD. recalled 11,520 cartons of Vista Meibo Tears Eye Drops on December 31, 2025. The recall occurred due to lack of assurance of sterility, posing a high risk to consumers. The affected product was distributed nationwide in the USA.
BioGlo Fluorescein Sodium Ophthalmic Strips are recalled due to sterility issues. The recall affects 184,320 containers distributed nationwide in the USA. Consumers should stop using the product immediately.
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Hard corn starch lumps were found in the product
Subpotent Drug: Due oxidation caused by leakage of the contents of the Icosapent Ethyl 1g capsules. Use of the affected product may lead to inconsistent therapeutic effects and an increase in potential gastrointestinal side effects in some patients.
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
Failed Impurities/Degradation Specifications: Out of specification result was obtained for the known impurity D.
Intuitive Surgical recalled 47 da Vinci 5 Surgeon Console Viewer Displays on December 30, 2025. The devices may lose display functionality, risking surgical injury. Healthcare providers should stop using the consoles immediately and follow recall instructions.
Cyber vulnerability of BLE communication was found by CISA VDP program.
Siemens Medical Solutions USA recalled five LUMINOS Q.namix T X-ray systems on December 29, 2025. The recall affects devices that can process images from previous patients due to a software issue. Healthcare providers must stop using these devices immediately.
Ortho images acquired with preset automatic horizontal flip are not flipped and when acquiring single images, there is the possibility that an image of a previous patient may be processed.
Cyber vulnerability of BLE communication was found by CISA VDP program.
Incorrect Product Formulation: product did not contain insulin as listed in the label.
CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
Potential exposure of rodents and rodent activity in the distribution center.
CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
Gold Star Distribution recalled Claritin, 20 Count, on December 26, 2025, due to insanitary conditions resulting from rodent exposure. The recall affects an unknown quantity distributed nationwide. Consumers should stop using the product immediately.